DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: BAY 3547926
Drug: BAY 3547922

First Posted Date: 2025-01-08

Last Posted Date: 2025-05-14

Lead Sponsor: Bayer

Target Recruit Count: 148

Registration Number: NCT06764316

Locations: 🇫🇮
Tampere University Hospital, Tampere, Finland
🇫🇮
Turku University Hospital, Turku, Finland
🇨🇦
University of Alberta - Cross Cancer Institute (CCI), Edmonton, Alberta, Canada

and more 5 locations

Expanded Access to Provide BAY2927088 for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Conditions: Advanced Non-small Cell Lung Cancer
Cancer

First Posted Date: 2025-01-07

Last Posted Date: 2025-04-29

Lead Sponsor: Bayer

Registration Number: NCT06761976

A Study to Learn More About How Well Treatment With BAY2927088 Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Phase 2

Recruiting

Conditions: Advanced Solid Tumors
HER2 Mutation

Interventions: Drug: BAY2927088

First Posted Date: 2025-01-07

Last Posted Date: 2025-04-30

Lead Sponsor: Bayer

Target Recruit Count: 111

Registration Number: NCT06760819

Locations: 🇨🇭
Hopitaux Universitaires de Geneve, Genève, Switzerland
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
City of Hope - Duarte Cancer Center, Duarte, California, United States

and more 48 locations

An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin

Completed

Conditions: Dermatitis, Atopic

First Posted Date: 2024-12-24

Last Posted Date: 2025-01-17

Lead Sponsor: Bayer

Target Recruit Count: 300

Registration Number: NCT06747897

Locations: 🇬🇧
IQVIA Ltd., London, United Kingdom

An Observational Study to Learn More About How Menopause Affects Women's Sleep and How They Are Being Treated for Sleep Problems

Recruiting

Conditions: Sleep Disturbances Associated With Menopause

First Posted Date: 2024-12-11

Last Posted Date: 2025-04-30

Lead Sponsor: Bayer

Target Recruit Count: 1000

Registration Number: NCT06728332

Locations: 🇺🇸
Bayer, Whippany, New Jersey, United States

An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan

Active, not recruiting

Conditions: Chronic Heart Failure
Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: vericiguat (BAY 1021189)

First Posted Date: 2024-11-20

Last Posted Date: 2025-04-30

Lead Sponsor: Bayer

Target Recruit Count: 7000

Registration Number: NCT06697353

Locations: 🇯🇵
Many Locations, Multiple Locations, Japan

A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

Recruiting

Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Low-volume Metastasis

Interventions: Drug: Darolutamide (BAY1841788) + docetaxel + ADT

First Posted Date: 2024-10-28

Last Posted Date: 2025-05-21

Lead Sponsor: Bayer

Target Recruit Count: 100

Registration Number: NCT06661122

Locations: 🇯🇵
Many locations, Multiple Locations, Japan

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Phase 1

Recruiting

Conditions: Advanced Solid Tumors Harboring KRAS G12C Mutation

Interventions: Drug: BAY3498264

First Posted Date: 2024-10-26

Last Posted Date: 2025-05-21

Lead Sponsor: Bayer

Target Recruit Count: 104

Registration Number: NCT06659341

Locations: 🇪🇸
Institut Catala D'oncologia - Hematologia, L Hospitalet De Llobregat, Barcelona, Spain
🇦🇺
Border Medical oncology - Albury Wodonga Regional Cancer Centre, Albury, New South Wales, Australia
🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica, Roma, Lazio, Italy

and more 7 locations

A Study to Learn if There is a Difference in the Blood Levels of Acetylsalicylic Acid When Taken as Different Chewable Tablets on an Empty Stomach by Healthy Participants

Phase 1

Completed

Conditions: Bioequivalence
Healthy Volunteers
Platelet Aggregation Inhibition

Interventions: Drug: Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)
Drug: Acetylsalicylic Acid (BAYE004465, UI1615160)

First Posted Date: 2024-10-23

Last Posted Date: 2025-04-15

Lead Sponsor: Bayer

Target Recruit Count: 38

Registration Number: NCT06655194

Locations: 🇲🇽
IPharma, S.A. de C.V., Monterrey, Nuevo Leon, Mexico

An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions

Not yet recruiting

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Worsening Chronic Heart Failure

Interventions: Drug: Vericiguat (Verquvo, BAY1021189)

First Posted Date: 2024-10-09

Last Posted Date: 2025-05-04

Lead Sponsor: Bayer

Target Recruit Count: 1200

Registration Number: NCT06632483

Locations: 🇮🇳
Many locations, Multiple Locations, India

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy